biostudies-literatureUnknown19(1)Chan YH<h4>Background</h4>Evidence of adverse clinical outcomes for non-vitamin K antagonist oral anticoagulant (NOACs) and warfarin in patients with atrial fibrillation (AF) and diabetes mellitus are limited. We investigated the effectiveness, safety, and major adverse limb events for NOACs versus warfarin among diabetic AF patients.<h4>Methods</h4>In this nationwide retrospective cohort study collected from Taiwan National Health Insurance Research Database, we identified a total of 20,967 and 5812 consecutive AF patients with diabetes taking NOACs and warfarin from June 1, 2012, to December 31, 2017, respectively. We used propensity-score stabilized weighting to balance covariates across study groups.<h4>Results</h4>NOAC was associated with a lower risk of major adverse cardiovascular events (Cardiovascular diabetology63https://www.ebi.ac.uk/biostudies/studies/S-EPMC7222472biostudies-literatureEffectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.PMC7222472Kuo CTWu LSLip GYHLi PRChang SHSee LCChao TFLiu JRYeh YHChan YHLee HFfalseEffectiveness, safety, and major adverse limb events in atrial fibrillation patients with concomitant diabetes mellitus treated with non-vitamin K antagonist oral anticoagulants.<h4>Background</h4>Evidence of adverse clinical outcomes for non-vitamin K antagonist oral anticoagulant (NOACs) and warfarin in patients with atrial fibrillation (AF) and diabetes mellitus are limited. We investigated the effectiveness, safety, and major adverse limb events for NOACs versus warfarin among diabetic AF patients.<h4>Methods</h4>In this nationwide retrospective cohort study collected from Taiwan National Health Insurance Research Database, we identified a total of 20,967 and 5812 consecutive AF patients with diabetes taking NOACs and warfarin from June 1, 2012, to December 31, 2017, respectively. We used propensity-score stabilized weighting to balance covariates across study groups.<h4>Results</h4>NOAC was associated with a lower risk of major adverse cardiovascular events (2020-01-01T00:00:00Z2020 May2025-04-25T21:38:14.482Z2020-05-24T07:10:09ZS-EPMC72224723240416810.1186/s12933-020-01043-2